



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



Conivaptan (hydrochloride)

Item No. 23728

CAS Registry No.: 168626-94-6
Formal Name: N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-[1,1'-biphenyl]-2-carboxamide, monohydrochloride
Synonym: YM-087
MF: C₃₂H₂₆N₄O₂ • HCl
FW: 535.0
Purity: ≥95%
Supplied as: A solid
Storage: 4°C
Stability: ≥1 year



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Conivaptan (hydrochloride) is supplied as a solid. A stock solution may be made by dissolving the conivaptan (hydrochloride) in the solvent of choice. Conivaptan (hydrochloride) is slightly soluble in methanol and DMSO.

Description

Conivaptan is an antagonist of the arginine vasopressin (AVP) receptors V_{1A} and V₂ (K_is = 0.48 and 3.04 nM for rat liver V_{1A} and kidney V₂, respectively).¹ It also competitively inhibits oxytocin binding to rat uterine oxytocin receptors (K_i = 44 nM) but has no effect on AVP binding to anterior pituitary V_{1B} receptors at concentrations up to 100 μM in a radioligand binding assay. Conivaptan suppresses AVP-induced increases in intracellular calcium in vascular smooth muscle cells (VSMCs) *in vitro* and the pressor response in pithed rats. Conivaptan (0.01-0.3 mg/kg, i.v.) increases urine output and decreases urine osmolality in dehydrated conscious rats in a dose-dependent manner. It also reduces brain edema and blood-brain barrier disruption in a mouse experimental stroke model.²

References

1. Tahara, A., Tomura, Y., Wada, K.-I., *et al.* Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V_{1A} and V₂ receptor antagonist, *in vitro* and *in vivo*. *J. Pharmacol. Exp. Ther.* **282**(1), 301-308 (1997).
2. Zeynalov, E., Jones, S.M., Seo, J.W., *et al.* Arginine-vasopressin receptor blocker conivaptan reduces brain edema and blood-brain barrier disruption after experimental stroke in mice. *PLoS One* **10**(8), e0136121 (2015).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/29/2017

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM